Psoriatic Arthritis

The Cutaneous Connection: Episode 30- Impact of the JAK Inhibitor Approval Delays
September 02, 2021

Mark Lebwohl, MD, takes a deep dive in the recent delay in approval for multiple JAK inhibitor drugs for treatment of inflammatory skin conditions such as psoriasis and atopic dermatitis. He also discusses the impact of the delay, as well as the benefits of JAK inhibitors for inflammatory skin diseases, and an outlook for the future of this drug class.

FDA Requiring Black Box Warning for Certain JAK Inhibitors
September 02, 2021

The FDA is now requiring black box warning for certain JAK inhibitors used to treat arthritis. This news comes amid delay in FDA approval for multiple JAK inhibitors for the treatment of inflammatory skin conditions.

FDA Delays Impacting Inflammatory Skin Disease Community
August 06, 2021

Mark Lebwohl, MD, explains the recent delay in approval of JAK inhibitors by the FDA, how it is affecting the inflammatory skin disease community, and if physicians should be concerned.